IRIS
GEROLDI, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.833
EU - Europa 1.506
AS - Asia 903
OC - Oceania 4
AF - Africa 1
Totale 4.247
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.826
CN - Cina 890
IE - Irlanda 460
UA - Ucraina 297
FI - Finlandia 238
DE - Germania 166
GB - Regno Unito 100
SE - Svezia 90
IT - Italia 84
FR - Francia 33
BE - Belgio 24
NL - Olanda 9
CA - Canada 7
IN - India 6
AU - Australia 4
JP - Giappone 3
RU - Federazione Russa 2
TR - Turchia 2
ES - Italia 1
ID - Indonesia 1
IR - Iran 1
MU - Mauritius 1
PL - Polonia 1
RO - Romania 1
Totale 4.247
Salva come PNG Salva come JPEG
Città #
Dublin 460
Chandler 457
Jacksonville 337
Nanjing 272
Ann Arbor 116
Beijing 110
Nanchang 104
Ashburn 95
Helsinki 93
Princeton 80
Lawrence 73
Hebei 70
Shenyang 69
Medford 66
Changsha 63
Jiaxing 54
Boardman 49
Wilmington 49
Tianjin 39
Hangzhou 37
New York 33
Woodbridge 29
Brussels 24
Verona 22
Milan 21
Shanghai 21
Norwalk 18
Seattle 17
Des Moines 12
Auburn Hills 10
Fairfield 10
Pavia 10
Los Angeles 9
Washington 7
Jinan 6
Taizhou 6
Toronto 6
Kunming 5
Ningbo 5
Zhengzhou 5
Berlin 4
Hanover 4
Ichibancho 3
Lanzhou 3
Naples 3
Orange 3
Canberra 2
Changchun 2
Falkenstein 2
Groningen 2
Gunzenhausen 2
Houston 2
Lincoln 2
Portland 2
San Francisco 2
Aberdare 1
Almere Stad 1
Amsterdam 1
Ardabil 1
Bloomfield 1
Borås 1
Bovisio Masciago 1
Brescia 1
Busto Arsizio 1
Crotone 1
Delray Beach 1
Fuzhou 1
Gdansk 1
Indianapolis 1
Jakarta 1
Jinhua 1
Logan 1
Melbourne 1
Modena 1
New Haven 1
Ottawa 1
Paris 1
Perugia 1
Phoenix 1
Pomezia 1
Pune 1
Redwood City 1
Reghin 1
Stanton 1
Tappahannock 1
Zogno 1
Totale 3.038
Salva come PNG Salva come JPEG
Nome #
Plasma eotaxin concentrations are associated with angiographic severity of coronary artery disease 91
Decreased NT-3 plasma levels and platelet serotonin content in patients with hypochondriasis 90
Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. 88
Significato prognostico dei livelli plasmatici di osteopontina in pazienti con angina pectoris stabile 81
Relationship between plasma levels of soluble receptor for advanced glycation end products (sRAGE) and coronary artery disease 81
Diabetes mellitus and silent myocardial ischemia in patients with coronary artery disease: comparison between patients with and without simptoms during provocative test. 80
Relationship between apolipoprotein(a) size polimorphism and coronary heart disease in overweight subjects 78
RAGE : a central player in nondiabetic vascular disease 77
La chemochina regolatoria eotaxina-3 quale nuovo fattore predittivo di outcome cardiovascolare in pazienti con angina pectoris stabile 75
Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men 74
Apo(a) isoforms: a genetic marker for progression of coronary atherosclerosis. 74
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes 73
Absence of Kir6.1/KCNJ8 mutations in Italian patients with abnormal coronary vasomotion 73
Approccio genetico-clinico alla cardiopatia ischemica: analisi di 14 casi familiari. 72
Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension 71
The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin:contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. 70
A novel Val734Ile variant in the ABCC9 gene associated with myocardial infarction 70
Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: A 5 year follow-up study 70
The regulatory chemokine eotaxin-3 is a novel predictor of cardiovascular outcome in patients with coronary artery disease 69
Analisi mutazionale di Kir6.1/KCNJ8 in pazienti con angina vasospastica 69
Raised plasma nerve growth factor levels associated with early-stage romantic love 68
374T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis 68
Disfunzione erettile come predittore di eventi cardiovascolari maggiori in diabetici con coronaropatia silente angiograficamente documentata 68
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary artery disease in Type 2 diabetic patients and in non-diabetic subjects 68
Forma solubile del recettore dei prodotti finali di glicazione avanzata (sRAGE) ed aterosclerosi coronarica 67
Functional proteomics of energy-linked enzymes in lymphocytes after stroke. 67
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 64
Association of lipoprotein(a) levels and apolipoprotein(a) phenotypes with coronary heart disease in patients with essential hypertension 64
Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients 62
Analysis of the apoliporotein(a) size polymorphism in patients with systemic lupus erythematosus 62
QT interval duration in apparently healthy men is associated with depression-related personality trait neuroticism 62
High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans 61
Circulating levels of osteopontin predicts future cardiac events in patients with chronic stable angina 61
Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target 60
Silent myocardial ischemia in diabetic and nondiabetic patients with coronary artery disease. 60
The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. 59
Circulating levels of soluble receptor for advanced glycation end products in neurodegenerative and vascular dementia 59
Cerebral ischemia and peripheral energy dysfunction in lymphocytes 58
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease 57
ATPases enzyme activities during ageing in different types of somatic and synaptic plasma membranes from rat frontal cerebral cortex 54
Matrix metalloproteinase 2 may be a marker of microangiopathy compared to metalloproteinase 9 in children and adolescents with type 1 diabetes mellitus: a 5-year follow-up study 54
Matrix metalloproteinase 2 and 9 evaluation in patients with or without diabetes during acute coronary syndrome and after the acute event 53
Enzyme activities in perikaryal and synaptic mitochondrial fractions from rat hippocampus during development 53
Action of piracetam and clonidine on different mitochondrial populations from hippocampus 53
Association between apolipoprotein(a) phenotypes and coronary heart disease at a young age. 53
Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk 52
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus 52
Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: a role for lipoprotein(a) and apolipoprotein(a) polymorphism. 52
Factors involved in drug interference on enzyme activities of three mitochondrial populations from rat hippocampus 50
Apolipoprotein(a) phenotypes and their predictive value for coronary heart disease: identification of an operative cut-off of apolipoprotein(a) polymorphism. 50
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 50
Fenotipi di apolipoproteina(a) come indicatori di suscettibilità genetica per rischio cardiovascolare in medicina del lavoro 50
Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. 50
Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease 50
The apolipoprotein(a) size polymorphism is assocated with Alzheimer's disease and vascular dementia 49
Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus 49
Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients 48
Peripheral energy dysfunction in cerebral ischemia: focus on lymphocytes. 47
Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects 46
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 45
Markers of eosinophilic inflammation and risk prediction in patients with coronary artery disease 45
Relationship between platelet serotonin content and rejections of unfair offers in the ultimatum game. 42
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 42
Energy metabolism of lymphocytes from acute stroke patients 42
Increased Plasma Aldosterone Concentrations in Patients with Clinical Depression 41
Prognostic significance of plasma osteopontin levels in patients with chronic stable angina 40
Genetic loading on human loving styles 40
Lymphocytes bioenergetics after stroke: a functional proteomic study 38
Restenosis after intracoronary stent placement: can apolipoprotein(a) polymorphism play a role? 38
Energy metabolism of mitochondria after ischemia and recovery times during aging and peripheral energy dysfunction in stroke patients: focus on lymphocytes 37
Mitochondrial Energy Metabolism of Brain and Lymphocytes after Ischemia and Recovery during Aging 30
Mitochondrial Energy Metabolism of Brain and Lymphocytes after Ischemia and Recovery during Aging 29
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes 27
Totale 4.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.920
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.920
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 0 1 7
2019/20201.088 293 424 6 55 1 62 8 54 10 102 67 6
2020/2021500 57 45 20 54 3 73 7 71 15 74 66 15
2021/2022326 7 3 9 8 2 5 8 20 16 19 49 180
2022/20231.338 139 107 17 98 149 124 0 78 556 17 34 19
2023/2024385 77 85 11 26 34 95 4 37 3 13 0 0
Totale 4.272